B2B: Five Practice-Changing Advances on the Horizon Summary
Author Contributions
Funding
Conflicts of Interest
Abbreviations
ADC | antibody-drug conjugate |
AI | artificial intelligence |
BCa | bladder cancer |
BCG | bacillus Calmette-Guérin |
ccRCC | clear cell renal cell carcinoma |
CI | confidence interval |
CN | cytoreductive nephrectomy |
CR | complete response |
ddMVAC | dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin |
DFS | disease-free survival |
EFS | event-free survival |
EV | enfortumab vedotin |
FDA | U.S. Food and Drug Administration |
FGFR | fibroblast growth factor receptor |
GC | gemcitabine-cisplatin |
HER2 | human epidermal growth factor receptor 2 |
HR | high risk |
ICG | indocyanine green |
ICI | immune checkpoint inhibitor |
IO | immunotherapy |
IR | intermediate risk |
KIM-1 | kidney injury molecule-1 |
LR | low risk |
MIBC | muscle-invasive bladder cancer |
mUC | metastatic urothelial carcinoma |
NAC | neoadjuvant chemotherapy |
NMIBC | non–muscle-invasive bladder cancer |
ORR | overall response rate |
OS | overall survival |
PCa | prostate cancer |
pCR | pathological complete response |
PFS | progression-free survival |
PLND | pelvic lymph node dissection |
RC | radical cystectomy |
RCC | renal cell carcinoma |
RCT | randomized controlled trial |
RFS | recurrence-free survival |
RT | radiotherapy |
SABR | stereotactic ablative body radiotherapy |
snoRNA | small nucleolar RNA |
TKI | tyrosine kinase inhibitor |
utDNA | urine tumour DNA |
References
- Powles, T.; Catto, J.W.; Galsky, M.D.; Al-Ahmadie, H.; Meeks, J.J.; Nishiyama, H.; Vu, T.Q.; Antonuzzo, L.; Wiechno, P.; Atduev, V.; et al. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. N. Engl. J. Med. 2024, 391, 1773–1786. [Google Scholar] [CrossRef] [PubMed]
- Pfister, C.; Gravis, G.; Flechon, A.; Chevreau, C.; Mahammedi, H.; Laguerre, B.; Guillot, A.; Joly, F.; Soulie, M.; Allory, Y.; et al. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): Survival endpoints at 5 years in an open-label, randomised, phase 3 study. Lancet Oncol. 2024, 25, 255–264. [Google Scholar] [CrossRef] [PubMed]
- Powles, T.; Valderrama, B.P.; Gupta, S.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Iyer, G.; Vulsteke, C.; Park, S.H.; Shin, S.J.; et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N. Engl. J. Med. 2024, 390, 875–888. [Google Scholar] [CrossRef] [PubMed]
- van der Heijden, M.S.; Sonpavde, G.; Powles, T.; Necchi, A.; Burotto, M.; Schenker, M.; Sade, J.P.; Bamias, A.; Beuzeboc, P.; Bedke, J.; et al. Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma. N. Engl. J. Med. 2023, 389, 1778–1789. [Google Scholar] [CrossRef]
- Hoimes, C.J.; Bedke, J.; Loriot, Y.; Nishiyama, H.; Fang, X.; Kataria, R.S.; Moreno, B.H.; Galsky, M.D. KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). J. Clin. Oncol. 2021, 39 (Suppl. S15), TPS4587. [Google Scholar] [CrossRef]
- Galsky, M.D.; Hoimes, C.J.; Necchi, A.; Shore, N.; Witjes, J.A.; Steinberg, G.; Bedke, J.; Nishiyama, H.; Fang, X.; Kataria, R.; et al. Perioperative Pembrolizumab Therapy in Muscle-Invasive Bladder Cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. Future Oncol. 2021, 17, 3137–3150. [Google Scholar] [CrossRef]
- van Rhijn, B.W.; Zuiverloon, T.C.; Vis, A.N.; Radvanyi, F.; van Leenders, G.J.; Ooms, B.C.; Kirkels, W.J.; Lockwood, G.A.; Boevé, E.R.; Jöbsis, A.C.; et al. Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non–Muscle-Invasive Bladder Cancer. Eur. Urol. 2010, 58, 433–441. [Google Scholar] [CrossRef]
- Catto, J.; Tran, B.; Rouprêt, M.; Gschwend, J.E.; Loriot, Y.; Nishiyama, H.; Redorta, J.P.; Daneshmand, S.; Hussain, S.A.; Cutuli, H.J.; et al. Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer. Ann. Oncol. 2024, 35, 98–106. [Google Scholar] [CrossRef]
- Vilaseca, A.; Jayram, G.; Raventos, C.; Shore, N.D.; Zainfeld, D.; Kang, T.W.; Ku, J.H.; Meeks, J.; Faba, O.R.; Roghmann, F.; et al. First safety and efficacy results of the TAR-210 erdafitinib intravesical delivery system in patients with non–muscle-invasive bladder cancer with select FGFR alterations. J. Urol. 2024, 211 (Suppl. S5), e987. [Google Scholar] [CrossRef]
- UroToday. AUA 2024: MoonRISe-1: Phase 3 study of TAR-210, an Erdafitinib Intravesical Delivery System, Versus Intravesical Chemotherapy in Patients with Intermediate-Risk Non–Muscle-Invasive Bladder Cancer with Susceptible FGFR Alterations. Available online: https://www.urotoday.com/conference-highlights/aua-2024/aua-2024-bladder-cancer/151836-aua-2024-moonrise-1-phase-3-study-of-tar-210-an-erdafitinib-intravesical-delivery-system-versus-intravesical-chemotherapy-in-patients-with-intermediate-risk-non-muscle-invasive-bladder-cancer-with-susceptible-fgfr-alterations.html (accessed on 28 October 2024).
- Oh, D.-Y.; Bang, Y.-J. HER2-targeted therapies—A role beyond breast cancer. Nat. Rev. Clin. Oncol. 2020, 17, 33–48. [Google Scholar] [CrossRef]
- Patelli, G.; Zeppellini, A.; Spina, F.; Righetti, E.; Stabile, S.; Amatu, A.; Tosi, F.; Ghezzi, S.; Siena, S.; Sartore-Bianchi, A. The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives. Cancer Treat Rev. 2022, 104, 102351. [Google Scholar] [CrossRef]
- Meric-Bernstam, F.; Makker, V.; Oaknin, A.; Oh, D.-Y.; Banerjee, S.; González-Martín, A.; Jung, K.H.; Ługowska, I.; Manso, L.; Manzano, A.; et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J. Clin. Oncol. 2024, 42, 47–58. [Google Scholar] [CrossRef] [PubMed]
- Galsky; Koshkin, V.; Campbell, M.; Drakaki, A.; Bowman, I.; Rose, A.; Brown, J.; Aragon-Ching, J.; Gadde, S.; Harandi, A.; et al. 1967MO Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C. Ann. Oncol. 2024, 35, S1138–S1139. [Google Scholar] [CrossRef]
- Salari, K.; Sundi, D.; Lee, J.J.; Wu, S.; Wu, C.L.; DiFiore, G.; Yan, Q.R.; Pienkny, A.; Lee, C.K.; Oberlin, D.; et al. Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk-prediction. Clin. Cancer Res. 2023, 29, 3668–3680. [Google Scholar] [CrossRef] [PubMed]
- St-Laurent, M.P.; Plets, M.; Black, P.C.; Singh, P.; McConkey, D.J.; Lucia, S.; Koshkin, V.S.; Stratton, K.L.; Bivalacqua, T.; Kassouf, W.; et al. Correlation of urinary comprehensive genomic profile with risk of recurrence of BCG-unresponsive non-muscle invasive bladder cancer treated with atezolizumab in SWOG S1605. J. Clin. Oncol. 2024, 42 (Suppl. S4), 529. [Google Scholar] [CrossRef]
- Plimack, E.R.; Rini, B.I.; Stus, V.; Gafanov, R.; Waddell, T.; Nosov, D.; Pouliot, F.; Soulieres, D.; Melichar, B.; Vynnychenko, I.; et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426. J. Clin. Oncol. 2020, 38 (Suppl. S15), 5001. [Google Scholar] [CrossRef]
- Motzer, R.J.; Tannir, N.M.; McDermott, D.F.; Burotto, M.; Choueiri, T.K.; Hammers, H.J.; Plimack, E.R.; Porta, C.G.; George, S.; Powles, T.B.; et al. 661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N + I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). Ann Oncol. 2021, 32, S685–S687. [Google Scholar] [CrossRef]
- Motzer, R.J.; Penkov, K.; Haanen, J.; Rini, B.; Albiges, L.; Campbell, M.T.; Venugopal, B.; Kollmannsberger, C.; Negrier, S.; Uemura, M.; et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 2019, 380, 1103–1115. [Google Scholar] [CrossRef]
- Méjean, A.; Ravaud, A.; Thezenas, S.; Colas, S.; Beauval, J.-B.; Bensalah, K.; Geoffrois, L.; Thiery-Vuillemin, A.; Cormier, L.; Lang, H.; et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N. Engl. J. Med. 2018, 379, 417–427. [Google Scholar] [CrossRef]
- Bex, A.; Mulders, P.; Jewett, M.; Wagstaff, J.; Van Thienen, J.V.; Blank, C.U.; Van Velthoven, R.; Del Pilar Laguna, M.; Wood, L.; Van Melick, H.H.E.; et al. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol. 2019, 5, 164–170. [Google Scholar] [CrossRef]
- Turajlic, S.; Xu, H.; Litchfield, K.; Rowan, A.; Chambers, T.; Lopez, J.I.; Nicol, D.; O’brien, T.; Larkin, J.; Horswell, S.; et al. Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. Cell 2018, 173, 581–594.e12. [Google Scholar] [CrossRef] [PubMed]
- Song, S.H.; Lee, S. Cytoreductive nephrectomy in the age of immunotherapy-based combination treatment. Investig. Clin. Urol. 2023, 64, 425–434. [Google Scholar] [CrossRef] [PubMed]
- Park, J.S.; Kim, J.; Jeon, J.; Lee, J.; Jang, W.S.; Lee, S.H.; Han, W.K.; Choi, Y.D.; Koo, K.C.; Cho, K.S.; et al. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in immune-oncology era (SEVURO-CN): Study protocol for a multi-center, prospective, randomized trial. Trials 2024, 25, 447. [Google Scholar] [CrossRef] [PubMed]
- Iisager, L.; Ahrenfeldt, J.; Donskov, F.; Ljungberg, B.; Bex, A.; Lund, L.; Lyskjær, I.; Fristrup, N. Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: The NORDIC-SUN-Trial. BMC Cancer 2024, 24, 1–8. [Google Scholar] [CrossRef]
- Bell, H.; Cotta, B.H.; Salami, S.S.; Kim, H.; Vaishampayan, U. “PROBE”ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer. Kidney Cancer J. 2022, 6, 3–9. [Google Scholar] [CrossRef]
- Runcie, K.; Singer, E.A.; Ornstein, M.C.; Anderson, C.B.; Dallos, M.; Hawley, J.; Lim, E.A.; Drake, C.G.; Izar, B.; Shaish, H.A.; et al. Cyto-KIK: A phase II trial of cytoreductive surgery in kidney cancer plus immunotherapy (nivolumab) and targeted kinase inhibition (cabozantinib). J. Clin. Oncol. 2021, 39 (Suppl. S15), TPS4598. [Google Scholar] [CrossRef]
- Xu, W.; Puligandla, M.; Halbert, B.; Haas, N.B.; Flaherty, K.T.; Uzzo, R.G.; Dutcher, J.P.; DiPaola, R.S.; Sabbisetti, V.; Bhatt, R.S. Plasma KIM-1 is associated with recurrence risk after nephrectomy for localized renal cell carcinoma: A trial of the ECOG-ACRIN Research Group (E2805). Clin. Cancer Res. 2021, 27, 3397–3403. [Google Scholar] [CrossRef]
- Pal, S.K.; Uzzo, R.; Karam, J.A.; Master, V.A.; Donskov, F.; Suarez, C.; Albiges, L.; Rini, B.; Tomita, Y.; Kann, A.G.; et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): A multicentre, randomised, double-blind, phase 3 trial. Lancet 2022, 400, 1103–1116. [Google Scholar] [CrossRef]
- Motzer, R.J.; Powles, T.; Atkins, M.B.; Escudier, B.; McDermott, D.F.; Alekseev, B.Y.; Lee, J.-L.; Suarez, C.; Stroyakovskiy, D.; De Giorgi, U.; et al. Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. JAMA Oncol. 2022, 8, 275–280. [Google Scholar] [CrossRef]
- Beckermann, K.; Haake, S.; Reddy, A.; Shyr, Y.; Rathmell, W.K.; Pal, S.; Ornstein, M.; Barata, P.; Zhang, T.; Rini, B. OPtimal treatment by invoking biologic clusters in renal cell carcinoma (OPTIC RCC). Oncologist 2023, 28 (Suppl. S1), S14. [Google Scholar] [CrossRef]
- Jonasch, E.; Donskov, F.; Iliopoulos, O.; Rathmell, W.K.; Narayan, V.K.; Maughan, B.L.; Oudard, S.; Else, T.; Maranchie, J.K.; Welsh, S.J.; et al. Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease. N. Engl. J. Med. 2021, 385, 2036–2046. [Google Scholar] [CrossRef] [PubMed]
- Albiges, L.; Rini, B.; Peltola, K.; De Velasco Oria, G.A.; Burotto, M.; Rodriguez, C.S.; Ghatalia, P.; Iacovelli, R.; Lam, E.; Verzoni, E.; et al. LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study. Ann. Oncol. 2023, 34, S1329–S1330. [Google Scholar] [CrossRef]
- Choueiri, T.K.; Powles, T.; Peltola, K.; de Velasco, G.; Burotto, M.; Suarez, C.; Ghatalia, P.; Iacovelli, R.; Lam, E.T.; Verzoni, E.; et al. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 2024, 391, 710–721. [Google Scholar] [CrossRef] [PubMed]
- Choueiri, T.K.; Powles, T.; Voss, M.H.; Plimack, E.R.; Gurney, H.; Song, Y.; Perini, R.F.; Rodriguez-Lopez, K.; Rini, B.I. LITESPARK-012: Pembrolizumab Plus Lenvatinib With or Without Belzutifan or Quavonlimab for Advanced Renal Cell Carcinoma. Futur. Oncol. 2023, 19, 2631–2640. [Google Scholar] [CrossRef]
- Siva, S.; Louie, A.V.; Kotecha, R.; Barber, M.N.; Ali, M.; Zhang, Z.; Guckenberger, M.; Kim, M.S.; Scorsetti, M.; Tree, A.C.; et al. Stereotactic body radiotherapy for primary renal cell carcinoma: A systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS). Lancet Oncol. 2024, 25, e18–e28. [Google Scholar] [CrossRef]
- Siva, S.; Bressel, M.; Wood, S.T.; Shaw, M.G.; Loi, S.; Sandhu, S.K.; Tran, B.; Azad, A.A.; Lewin, J.H.; Cuff, K.E.; et al. Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma—The RAPPORT Trial. Eur. Urol. 2022, 81, 364–372. [Google Scholar] [CrossRef]
- Siva, S.; Bressel, M.; Sidhom, M.; Sridharan, S.; Vanneste, B.G.L.; Davey, R.; Montgomery, R.; Ruben, J.; Foroudi, F.; Higgs, B.; et al. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): A non-randomised phase 2 trial. Lancet Oncol. 2024, 25, 308–316. [Google Scholar] [CrossRef]
- Margulis, V.; Freifeld, Y.; Pop, L.M.; Manna, S.; Kapur, P.; Pedrosa, I.; Christie, A.; Mohamad, O.; Mannala, S.; Singla, N.; et al. Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus—Safety Lead-in Results of a Phase 2 Trial. Int. J. Radiat. Oncol. Biol Phys. 2021, 110, 1135–1142. [Google Scholar] [CrossRef]
- Yang, D.X.; Hannan, R. Harnessing stereotactic precision in the fight against primary kidney cancer: Time for a randomised trial? Lancet Oncol. 2024, 25, 267–269. [Google Scholar] [CrossRef]
- Morka, N.; Berger, L.; Hyde, E.; Mumtaz, F.; Barod, R.; Patki, P.; Graafland, N.; Hendricksen, K.; Tran, M.; Bex, A. Interactive virtual 3D image reconstruction to assist renal surgery in patients with fusion anomalies of the kidney. J. Clin. Urol. 2023, 16, 340–343. [Google Scholar] [CrossRef]
- Berger, L.; Hyde, E.; Gibb, M.; Pavithran, N.; Kelly, G.; Mumtaz, F.; Ourselin, S. Boosted Training of Convolutional Neural Networks for Multi-Class Segmentation. Published Online 13 June 2018. Available online: https://arxiv.org/abs/1806.05974v2 (accessed on 10 November 2024).
- Berger, L.; Hyde, E.; Pavithran, N.; Mumtaz, F.; Bragman, F.; Cardoso, M.J.; Ourselin, S. How to Control the Learning Rate of Adaptive Sampling Schemes. Published Online 8 April 2018. Available online: https://openreview.net/forum?id=r1V_ovvjG (accessed on 10 November 2024).
- Schiavina, R.; Bianchi, L.; Chessa, F.; Barbaresi, U.; Cercenelli, L.; Lodi, S.; Gaudiano, C.; Bortolani, B.; Angiolini, A.; Bianchi, F.M.; et al. Augmented reality to guide selective clamping and tumour dissection during robot-assisted partial nephrectomy: A preliminary experience. Clin. Genitourin Cancer 2021, 19, E149–E155. [Google Scholar] [CrossRef] [PubMed]
- Amparore, D.; Checcucci, E.; Piazzolla, P.; Piramide, F.; De Cillis, S.; Piana, A.; Verri, P.; Manfredi, M.; Fiori, C.; Vezzetti, E.; et al. Indocyanine green drives computer vision based 3D augmented reality robot assisted partial nephrectomy: The beginning of “automatic” overlapping era. Urology 2022, 164, e312–e316. [Google Scholar] [CrossRef] [PubMed]
- Amparore, D.; Sica, M.; Verri, P.; Piramide, F.; Checcucci, E.; De Cillis, S.; Piana, A.; Campobasso, D.; Burgio, M.; Cisero, E.; et al. Computer vision and machine-learning techniques for automatic 3D virtual images overlapping during augmented reality guided robotic partial nephrectomy. Technol. Cancer Res. Treat. 2024, 23, 15330338241229368. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Published by MDPI on behalf of the Société Internationale d’Urologie. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Black, P.C.; Mumtaz, F.; Tanguay, S. B2B: Five Practice-Changing Advances on the Horizon Summary. Soc. Int. Urol. J. 2025, 6, 20. https://doi.org/10.3390/siuj6010020
Black PC, Mumtaz F, Tanguay S. B2B: Five Practice-Changing Advances on the Horizon Summary. Société Internationale d’Urologie Journal. 2025; 6(1):20. https://doi.org/10.3390/siuj6010020
Chicago/Turabian StyleBlack, Peter C., Faiz Mumtaz, and Simon Tanguay. 2025. "B2B: Five Practice-Changing Advances on the Horizon Summary" Société Internationale d’Urologie Journal 6, no. 1: 20. https://doi.org/10.3390/siuj6010020
APA StyleBlack, P. C., Mumtaz, F., & Tanguay, S. (2025). B2B: Five Practice-Changing Advances on the Horizon Summary. Société Internationale d’Urologie Journal, 6(1), 20. https://doi.org/10.3390/siuj6010020